BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35752523)

  • 1. Sacral neuromodulation: Rechargeable versus non-rechargeable device. What would the patient preferences be in France?
    Gamé X; Ruffion A; Cornu JN; Phé V; Peyronnet B; Perrouin-Verbe MA; Aublant C; Adé A; Chartier-Kastler E
    Prog Urol; 2022 Sep; 32(10):672-680. PubMed ID: 35752523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator.
    Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J
    Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy of sacral neuromodulation in the treatment of voiding dysfunction after endometriosis surgery.
    Aublé A; Gazdovich S; Dégremont S; Pfister C; Roman H; Bridoux V; Leroi AM; Cornu JN
    Prog Urol; 2023 Dec; 33(17):1073-1082. PubMed ID: 37951811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
    Girtner F; Burger M; Mayr R
    Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacral neuromodulation system for treating refractory overactive bladder.
    Phillips A
    Br J Nurs; 2020 Oct; 29(18):S30-S37. PubMed ID: 33035097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
    McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
    J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome.
    Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB
    Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
    Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
    Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
    Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of factors that influence patient preference of third-line therapy for overactive bladder.
    Kapur A; Harandi AA; Cohen T; Ruan H; Dabrowski C; Anderson R; Hwang K; Lee E; Weissbart S; Kim J
    Neurourol Urodyn; 2022 Nov; 41(8):1906-1913. PubMed ID: 36104866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Functional results and satisfaction in 44 patients after implantation of a NS3-type sacral neurostimulator for refractory idiopathic overactive bladder followed at 43 months, single-center series].
    Msika J; Kalantan M; Larre S; Leon P
    Prog Urol; 2021 Oct; 31(12):725-731. PubMed ID: 33962849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction.
    Cohn JA; Kowalik CG; Kaufman MR; Reynolds WS; Milam DF; Dmochowski RR
    Expert Rev Med Devices; 2017 Jan; 14(1):3-14. PubMed ID: 27915486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Technologies and Applications in Sacral Neuromodulation: An Update.
    De Wachter S; Knowles CH; Elterman DS; Kennelly MJ; Lehur PA; Matzel KE; Engelberg S; Van Kerrebroeck PEV
    Adv Ther; 2020 Feb; 37(2):637-643. PubMed ID: 31875299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study.
    Goudelocke C; Xavier K; Pecha B; Burgess K; Perrouin-Verbe MA; Krlin R; Michaels J; Shah S; Peyronnet B; Zaslau S; Champs M; Papi B; Bittner K; Elterman D; Nitti V
    Neurourol Urodyn; 2023 Apr; 42(4):761-769. PubMed ID: 36917003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged percutaneous SNM testing does not cause infection-related explanation.
    Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
    BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensing in Sacral Neuromodulation: A Feasibility Study in Subjects With Urinary Incontinence and Retention.
    Goudelocke C; Jungbauer Nikolas LM; Bittner KC; Offutt SJ; Miller AE; Slopsema JP
    Neuromodulation; 2024 Feb; 27(2):392-398. PubMed ID: 37589643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of sacral neuromodulation: a treatment for patients with symptoms of lower urinary tract dysfunction.
    Fletcher N
    Br J Nurs; 2020 Aug; 29(15):848-856. PubMed ID: 32790556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.